Results 111 to 120 of about 3,507,689 (226)

[Antithrombin III].

open access: yesAnnales de biologie clinique, 1987
The in vivo regulation of coagulation is mainly controlled by plasma inhibitors in which antithrombin III (AT III) plays an importance role. AT III is a glycoprotein which inhibits all serine proteases, except factor, VIIa, generated during the coagulation process. The proteases are inactivated by formation of an equimolecular complex and this reaction
C, Boyer-Neumann, M, Wolf, M J, Larrieu
openaire   +3 more sources

Post‐Market Analysis of the Xenios Console With the Xlung Tubing Kit 230 for Extracorporeal Membrane Oxygenation After Cardiac Surgery

open access: yesArtificial Organs, Volume 50, Issue 10, Page 1464-1475, October 2026.
This study is a comprehensive post‐market analysis of the Xenios console and XLung kit 230 preconfigured ECMO tubing set in post‐cardiotomy applications. The performance of this device was evaluated and demonstrated in all key clinical areas, with an adequate safety profile.
Luca Conci   +9 more
wiley   +1 more source

The Role of Thalassaemic Red Cells in the Mechanism Process of Hypercoagulable State in Thalassaemia

open access: yesThalassemia Reports
Background: Thromboembolic events (TEEs) are recognized complications in thalassaemia, arising from a hypercoagulable state driven by multiple proposed mechanisms.
Wardah Roslan   +11 more
doaj   +1 more source

Antithrombin-III and platelets in hemodialysis patients

open access: yes, 1981
Plasma antithrombin-III (AT-III) levels in 18 patients on maintenance hemodialysis were studied. AT-III was measured functionally and immunologically before and after dialysis. Simultaneous counts of platelets were made.
Sorensen, L. H.   +2 more
core   +1 more source

Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy

open access: yesHaematologica, 2006
BACKGROUND AND OBJECTIVES: Hepatic veno-occlusive disease (VOD) remains a serious complication after hematopoietic stem cell transplantation (HSCT). Based on a protective effect of antithrombin III (ATIII) on endothelial cells, we assessed the incidence ...
U Haussmann   +5 more
doaj  

Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells.

open access: yes, 1994
Thrombin has attracted increasing attention as a possible mitogen for vascular smooth muscle cells in lesion development both after vascular injury and in atherogenesis. In this study, the ability of antithrombin III to inhibit alpha-thrombin-induced DNA
J Sanchez   +4 more
core   +1 more source

Estrogen-induced deficiency and decrease in antithrombin III activity in patients with prostatic cancer

open access: yes, 1982
Plasma antithrombin III activity was studied in 22 patients with prostatic cancer who were on estrogen therapy. Normal plasma antithrombin III activity varies between 0.80 and 1.40 U. per ml. A loading dose of 15 mg.
Dabhoiwala, N. F.   +4 more
core  

Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?

open access: yes, 2003
This study was carried out to determine whether the administration of antithrombin III decreases the risk of intraventricular hemorrhage in premature infants.
GITTO, Eloisa   +7 more
core   +1 more source

Prognostic Value of Anti-Thrombin III Level in Neonatal Sepsis

open access: yesJournal of Rawalpindi Medical College, 2016
Background: To determine levels of Antithrombin III and its prognostic value in predicting neonatal sepsis. Methods: In this descriptive study full term neonates (n=70)were recruited.
Sidra Tul Muntaha
doaj  

Hubungan Derajat Skor Curb-65 Saat Awal Masuk pada Pasien Pneumonia Komunitas terhadap Nilai Antithrombin III (AT-III)

open access: yes, 2013
Background The assessment of level severity in patient with community acquired pneumonia (CAP) is very important to determine the next management of disease.
Andriyani, Sari
core   +3 more sources

Home - About - Disclaimer - Privacy